- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Evolus is a drug manufacturers - specialty & generic business based in the US. Evolus shares (EOLS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $11.35 – an increase of 4.22% over the previous week. Evolus employs 322 staff and has a trailing 12-month revenue of around $248.3 million.
Our top picks for where to buy Evolus stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy Evolus stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – EOLS. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Evolus stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Evolus stock price (NASDAQ: EOLS)
Use our graph to track the performance of EOLS stocks over time.Evolus shares at a glance
Information last updated 2024-12-26.
| Latest market close | $11.35 |
|---|---|
| 52-week range | $9.80 - $17.82 |
| 50-day moving average | $13.75 |
| 200-day moving average | $13.53 |
| Wall St. target price | $23.43 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.91 |
Is it a good time to buy Evolus stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Evolus price performance over time
Historical closes compared with the close of $10.85 from 2024-12-24
| 1 week (2024-12-20) | -0.37% |
|---|---|
| 1 month (2024-11-27) | -21.38% |
| 3 months (2024-09-27) | -31.97% |
| 6 months (2024-06-27) | -0.73% |
| 1 year (2023-12-27) | 6.90% |
|---|---|
| 2 years (2022-12-27) | 66.41% |
| 3 years (2021-12-27) | 59.56% |
| 5 years (2019-12-27) | 11.89 |
Evolus financials
| Revenue TTM | $248.3 million |
|---|---|
| Gross profit TTM | $92.7 million |
| Return on assets TTM | -9.93% |
| Return on equity TTM | -861.68% |
| Profit margin | -22.33% |
| Book value | $0.09 |
| Market Capitalization | $718.7 million |
TTM: trailing 12 months
Evolus share dividends
We're not expecting Evolus to pay a dividend over the next 12 months.
Evolus share price volatility
Over the last 12 months, Evolus's shares have ranged in value from as little as $9.8 up to $17.82. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evolus's is 1.315. This would suggest that Evolus's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Evolus overview
Evolus, Inc. , a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California. .
Frequently asked questions
nullWhat percentage of Evolus is owned by insiders or institutions?
Currently 12.305% of Evolus shares are held by insiders and 80.219% by institutions. How many people work for Evolus?
Latest data suggests 322 work at Evolus. When does the fiscal year end for Evolus?
Evolus's fiscal year ends in December. Where is Evolus based?
Evolus's address is: 520 Newport Center Drive, Newport Beach, CA, United States, 92660 What is Evolus's ISIN number?
Evolus's international securities identification number is: US30052C1071 What is Evolus's CUSIP number?
Evolus's Committee on Uniform Securities Identification Procedures number is: 30052C107
More resources on Finder
More guides on Finder
-
Best Paper Trading Apps to Practice Trading With Fake Money in 2024
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
-
Sweep Accounts
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for Beginners: 9 Best Trading Platforms to Get Started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
5 Best International Stock Brokers to Invest in Foreign Assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
10 Best Stock Apps of 2024 to Elevate Your Mobile Trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 Best Brokerage Accounts for Trading and Investing in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Ask a question